Menu Search Donate
Guideline identity image

Blood Products - Viruses

This document is only valid for the day on which it is accessed. Please read our disclaimer.

CMV

As a result of universal leucodepletion, there is no need to use high-efficiency filters at the bedside or to request CMV negative products for oncology patients.

Risk of viral transmission

Parents often worry about the safety of blood products. The following table provides an estimate of risk:

Infection1  Window period (days)  Residual risk (/106 donations)
HIV  0.4 
HCV  0.4 
HBV 45 1.1
vCJD  Possible, but not yet reported in NZ

References

  1. NZBS Transfusion medicine handbook 2008.

Did you find this information helpful?

Document Control

  • Date last published: 20 April 2016
  • Document type: Clinical Guideline
  • Services responsible: National Child Cancer Network
  • Owner: Siobhan Cross
  • Review frequency: 2 years